Of the participants in the study, 83% of those with moderate to severe migraine were either pain-free or had only mild pain two hours after treatment with GelStat Migraine near migraine onset. Furthermore, no patients reported severe pain at the conclusion of two hours, with only 17% experiencing moderate pain.
Associated symptoms of migraine were eliminated in a number of patients, an effect mediated by the symptom type. Recurrence rate of headache of moderate to severe intensity was reported by relatively few patients and no significant side-effects were reported.
Among those who, prior to the study, routinely treated their migraine with a triptan (the prescription drug category generally considered to be the gold standard of migraine treatment) 41% preferred GelStat Migraine or felt it equal to that prior treatment.
Stephen Roberts, chairman and CEO of GelStat said the company expects “Consumer awareness and product adoption will continue to grow as a result of expanding distribution, new marketing initiatives and increasing third-party recognition of GelStat Migraine as a fast, effective and economical migraine medication.”